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Abstract
Background
Congenital bicuspid aortic valve (CBAV) is the main cause of aortic stenosis (AS) in young
adults. However, the histopathological features of AS in patients with CBAV have not been
fully investigated.
Methods and Results
We examined specimens of aortic valve leaflets obtained from patients who had undergone
aortic valve re/placement at our institution for severe AS with CBAV (n = 24, CBAV-AS
group), severe AS with tricuspid aortic valve (n = 24, TAV-AS group), and severe aortic
regurgitation (AR) with CBAV (n = 24, CBAV-AR group). We compared the histopatholog-
ical features among the three groups. Pathological features were classified using semi-
quantitative methods (graded on a scale 0 to 3) by experienced pathologists without knowl-
edge of the patients’ backgrounds. The severity of inflammation, neovascularization, and
calcium and cholesterol deposition did not differ between the CBAV-AS and TAV-AS
groups, and these four parameters were less marked in the CBAV-AR group than in the
CBAV-AS (all p<0.01). Meanwhile, the grade of valvular fibrosis was greater in the CBAV-
AS group, compared with the TAV-AS and CBAV-AR groups (both p<0.01). In AS patients,
thickness of fibrotic lesions was greater on the aortic side than on the ventricular side (both
p<0.01). Meanwhile, thickness of fibrotic lesions was comparable between the aortic and
ventricular sides in CBAV-AR patients (p = 0.35).
PLOS ONE | DOI:10.1371/journal.pone.0160208 August 1, 2016 1 / 11
a11111
OPEN ACCESS
Citation: Hamatani Y, Ishibashi-Ueda H, Nagai T,
Sugano Y, Kanzaki H, Yasuda S, et al. (2016)
Pathological Investigation of Congenital Bicuspid
Aortic Valve Stenosis, Compared with Atherosclerotic
Tricuspid Aortic Valve Stenosis and Congenital
Bicuspid Aortic Valve Regurgitation. PLoS ONE 11
(8): e0160208. doi:10.1371/journal.pone.0160208
Editor: Katherine Yutzey, Cincinnati Children's
Medical Center, UNITED STATES
Received: May 4, 2016
Accepted: July 17, 2016
Published: August 1, 2016
Copyright: © 2016 Hamatani et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper.
Funding: This work was supported by a grant from
the Japan Cardiovascular Research Foundation
(T.A.).
Competing Interests: The authors have declared
that no competing interests exist.
Conclusions
Valvular fibrosis, especially on the aortic side, was greater in patients with CBAV-AS than in
those without, suggesting a difference in the pathogenesis of AS between CBAV and TAV.
Introduction
Congenital bicuspid aortic valve (CBAV) is a common congenital heart malformation, with an
estimated prevalence between 0.5 and 2% [1, 2]. CBAV has been identified as the main cause of
aortic stenosis (AS) requiring surgical treatment in children and young adults. Despite its prev-
alence, the pathophysiology of AS in CBAV remains unclear [3].
In histological studies, stenotic aortic valve and atherosclerosis share several common fea-
tures, including lipid accumulation, calcification, infiltration of inflammatory cells and neovas-
cularization [4, 5]. The progression of AS in the tricuspid aortic valve (TAV) is associated with
traditional atherosclerotic risk factors [6, 7], and AS in TAVmight result from an active pro-
cess similar to atherosclerosis. To date, few data exist to explain the mechanisms of the devel-
opment of AS in patients with CBAV. Although atherosclerotic risk factors are also reported to
be associated with increased risk of AS in patients with CBAV [8], the precise mechanisms and
histopathological features of AS in patients with CBAV have not been fully elucidated.
In addition, CBAV is often associated with abnormalities of the ascending aortic media,
resulting in aortic bulb dilatation and aortic regurgitation (AR). Patients with AR develop
symptoms and undergo aortic valve replacement at a younger age compared with those with
AS. Histological comparison of AS and AR in CBAV patients could clarify the time course and
mechanisms of the development of AS in CBAV.
The aim of this study was to investigate the histopathological characteristics of AS in
patients with CBAV, compared with AS patients with TAV and AR patients with CBAV.
Materials and Methods
Study population and data collection
We examined specimens of aortic valve leaflets obtained from patients who had undergone
aortic valve replacement from April 2010 to September 2015 at our institution for severe AS
with CBAV (n = 24, CBAV-AS group). Groups comprising 24 patients with severely stenotic
TAV (TAV-AS group) and 24 CBAV patients with severe AR (CBAV-AR group) were enrolled
in parallel. We compared patients’ backgrounds and pathological characteristics among
patients with CBAV-AS, TAV-AS and CBAV-AR.
Valve tissue was collected at the time of the operation. Patients’ medical records were
reviewed to assess the clinical data. This study conformed to the principles outlined in the Dec-
laration of Helsinki. In this study, because patients’ information was anonymized and de-
identified prior to analyses, written informed consent was not obtained from each patient.
However, we publicized the study by posting a summary of the protocol on the website of the
National Cerebral and Cardiovascular Center, and clearly informed patients of their right to
refuse enrollment. The full study including these procedures for informed consent and enroll-
ment were approved by the Institutional Review Board of the National Cerebral and Cardiovas-
cular Center (M27-076).
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Definition of measurements
We reviewed clinical data in the patients’medical charts. Hypertension was diagnosed if periph-
eral blood pressure was>140/90 mmHg or if the patient was taking medication for hyperten-
sion. Diabetes mellitus was defined as HbA1c6.5% or receiving anti-diabetic medication.
Dyslipidemia was diagnosed if total cholesterol was>220 mg/dL, if low-density lipoprotein cho-
lesterol was>140 mg/dL, if triglyceride was>150 mg/dL, if high-density lipoprotein cholesterol
was<40 mg/dL, or if the patient was taking a lipid-lowering agent. All patients underwent car-
diac catheterization or coronary computed tomography angiography before operation. Coro-
nary artery disease was defined as coronary stenosis of at least 75% (in case of the left main
trunk, the cut off was 50%) detected by coronary angiography before the operation. All
patients also underwent trans-thoracic echocardiography before operation. Severe AS and
severe AR were defined according to the guidelines [9, 10]. Severe AR patients with moderate or
severe AS were excluded in this analysis. We also excluded patients complicated with infective
endocarditis.
Pathological analysis
The valve samples were obtained vertically through the valve cusps near the center of each leaflet.
The aortic valve was fixed in 10% buffered formalin and embedded in paraffin using standard
histological procedures. Representative lesions of the obtained materials were macroscopically
selected for further processing. The paraffin-embedded specimens were sectioned at 4–5 μm
thickness, and stained with hematoxylin-eosin (H&E) and Masson’s trichrome (MT) after decal-
cification with 10% EDTA solution. We assessed the following factors; neovascularization,
inflammation, calcification/cholesterol deposition, and valvular fibrosis. We also measured the
whole layer thickness of the valve and the thickness of fibrotic lesion (measured on the aortic
side and ventricular side) at the mid-portion of the leaflet.
Immunohistochemical examinations were performed on 4-5-μm-thick 10% buffered forma-
lin-fixed and paraffin-embedded tissue sections, using monoclonal antibodies to confirm
inflammation, neovascularization, calcification, and extracellular matrix deposit besides H&E
and MT stainings. All steps were performed using an auto-immunostainer, Bond-III (Leica,
Japan), according to the manufacturer’s instructions. All slides were incubated with primary
monoclonal antibodies against CD3 for T cells (Dako, Denmark) for 15 minutes. Representa-
tive samples were additionally incubated with primary antibodies against vonWillebrand fac-
tor (Dako, Japan) for endothelial cells (neovascularization), osteopontin (Leica, Japan) for
calcium deposits, and tenascin-C (4C-8, IBL, Japan), as the extracellular matrix which was
reportedly associated with progression of AS [11], followed by incubation with a mouse-rabbit-
horseradish peroxidase polymer and 3,3’- diaminobenzidine substrate. The sections were then
incubated in primer (anti-rabbit and anti-mouse) for 5 minutes. The primary antibody was
omitted from these protocols as a negative control. The sections were subsequently counter-
stained with hematoxylin-eosin.
Scoring of immunohistochemical and pathological features
Immunohistochemical and histopathological features were classified using semi-quantitative
methods (graded on a scale 0 to 3) by experienced pathologists without knowledge of the
patients’ clinical data. In terms of the semi-quantitative scoring of immunohistochemical stain-
ing, positive cells (for T cells)/area were classified as follows; grade 0 was no positive cells/area,
grade 1 was<25% cells positive/area, grade 2 was 25–50% cells positive/area, and grade 3
was> 50% cells positive/area [12]. The scoring for neovascularization was classified as follows:
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grade 0, absence; grade 1, isolated neovessels; grade 2, minimal aggregates; grade 3, abundant
neovessels [13].
Calcification was also graded on a scale of 0 to 3, as previously described. Briefly, grade 0
valves showed no calcification, grade 1 valves showed early calcific nodules, grade 2 valves
showed several calcific nodules with mild structural distortion, and grade 3 valves showed
many several calcific nodules with severe structural distortion [14, 15]. Valvular fibrosis was
graded as follows; grade 0: absent or minimal intensity of fibrotic tissue (representing about
less than 1% of the section), grade 1: slight intensity of fibrotic tissue (representing about
between 1 and 25% of the section), grade 2: moderate intensity of fibrotic tissue (representing
about between 25 and 50% of the section), grade 3: severe intensity of fibrotic tissue (represent-
ing about more than 50% of the section) according to a previous study [16].
Statistical analysis
Continuous variables are expressed as mean ± standard deviation. Categorical variables are
presented as numbers and percentages. Categorical variables were compared using the chi-
squared test when appropriate; otherwise, Fisher’s exact test was used. Continuous variables
were compared among the three groups using one-way analysis of variance. Histopathological
scores were analyzed using the Wilcoxon rank sum test. Bonferroni correction was used to
adjust for multiple comparison. Comparisons within groups were performed using paired t-
test. Multivariate linear regression modeling was used to adjust for suspected confounders. Rel-
evant covariates were selected for inclusion in multivariate models based on prior clinical
knowledge. JMP version 10 (SAS Institute, Cary, NC) was used to perform all analyses. Two-
sided p values less than 0.05 were considered statistically significant.
Results
Patients’ characteristics
A total of 24 patients with TAV-AS, 24 patients with CBAV-AS, and 24 patients with CBA-
V-AR were included in this study. Clinical characteristics, co-morbid conditions, echocardio-
graphic parameters, and laboratory data in the three groups are shown in Table 1. There were
some differences in baseline characteristics among the three groups. Patients with CBAV-AR
were more often male, younger, and had lower left ventricular ejection fraction (all p< 0.01).
Co-morbid conditions such as hypertension, diabetes mellitus, dyslipidemia, and coronary
artery disease were most prevalent in patients with TAV-AS (all p< 0.01).
Histological findings
Representative macroscopic images are shown in Fig 1. The severities of inflammation, neovas-
cularization, calcium deposition, cholesterol deposition, and fibrosis are shown in Table 2. In
patients with CBAV, the severity of the inflammation, neovascularization, calcium deposition,
and cholesterol deposition was higher in patients with CBAV-AS than in those with CBAV-AR
(all p< 0.01). Meanwhile, in patients with AS, the severity of inflammation, neovasculariza-
tion, calcium deposition, and cholesterol deposition did not differ between patients with CBA-
V-AS and those with TAV-AS (Table 2, Fig 2).
Valvular fibrosis was different among the three groups. Patients with CBAV-AS had more
marked valvular fibrosis than those with CBAV-AR (p< 0.01). In AS patients, valvular fibrosis
was more severe in patients with CBAV-AS compared with those with TAV-AS (p< 0.01,
Table 2, Fig 2). Intense tenascin-C deposition in the valve was observed in patients with CBA-
V-AS (Fig 2).
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Bicuspid morphology was independently associated with valvular fibrosis even after adjust-
ment for confounders such as age, sex, hypertension, diabetes mellitus, dyslipidemia, and
smoking history in multivariate linear regression analysis in AS patients (p< 0.01, Table 3).
Valvular thickness and thickness of fibrotic lesions in patients with CBAV
and TAV
Valvular thickness of whole zone and thickness of fibrotic lesions measured on the aortic side
and ventricular side are shown in Table 4. Valvular thickness was greatest in patients with
CBAV-AS and was thinnest in patients with CBAV-AR. Thickness of fibrotic lesions was also
greater in patients with CBAV-AS, compared with TAV-AS patients and CBAV-AR patients
(p< 0.01). In AS patients, valvular fibrosis was larger on the aortic side than on the ventricular
side (both p< 0.01). Meanwhile, valvular fibrosis was comparable between the aortic and ven-
tricular sides in CBAV-AR patients (p = 0.35).
Discussion
The major findings of this study were as follows: First, the severity of inflammation and neo-
vascularization was comparable between patients with CBAV-AS and those with TAV-AS, and
Table 1. Baseline characteristics of patients in three groups.
TAV-AS CBAV-AS CBAV-AR p value
Number 24 24 24
Baseline characteristics
Male 12 (50%) 14 (58%) 23 (96%) <0.01
Age (years) 77 ± 6 62 ± 13 39 ± 13 <0.01
Smoking history 9 (38%) 6 (25%) 8 (33%) 0.71
Co-morbid conditions
Hypertension 22 (92%) 9 (38%) 5 (20%) <0.01
Diabetes mellitus 9 (38%) 4 (17%) 0 (0%) <0.01
Dyslipidemia 20 (83%) 12 (50%) 7 (29%) <0.01
Coronary artery disease 10 (42%) 0 (0%) 0 (0%) <0.01
Ascending aorta diameter (mm) 33 ± 3 41 ± 5 38 ± 7 <0.01
Ascending aorta dilatation (45 mm) 0 (0%) 5 (21%) 3 (14%) 0.07
Echocardiographic parameters
LVEF (%) 61 ± 8 62 ± 7 52 ± 14 0.01
AVA (cm2) 0.72 ± 0.16 0.77 ± 0.26 - 0.37
Mean PG (mmHg) 47 ± 14 62 ± 26 - 0.02
Laboratory data
Estimated GFR (ml/m2) 52.3 ± 16.1 67.5 ± 9.2 69.4 ± 13.1 0.01
Blood urea nitrogen (mg/dl) 20 ± 8 16 ± 4 16 ± 6 0.01
Creatinine (mg/dl) 1.0 ± 0.6 0.8 ± 0.2 0.9 ± 0.2 0.16
HbA1c (%) 5.9 ± 0.8 5.7 ± 0.5 5.4 ± 0.4 0.01
Total cholesterol (mg/dl) 174 ± 41 185 ± 25 182 ± 29 0.47
LDL cholesterol (mg/dl) 97 ± 21 105 ± 17 108 ± 21 0.39
HDL cholesterol (mg/dl) 51 ± 19 55 ± 13 50 ± 14 0.57
Triglyceride (mg/dl) 115 ± 59 109 ± 48 136 ± 61 0.55
Categorical data are presented as number (%). Continuous data are presented as mean ± standard deviation. TAV; tricuspid aortic valve, AS; aortic
stenosis, CBAV; congenital bicuspid aortic valve, AR; aortic regurgitation, LVEF; left ventricular ejection fraction, AVA; aortic valve area, PG; pressure
gradient, GFR; glomerular ﬁltration ratio, HbA1c; hemoglobin A1c, LDL; low density lipoprotein, HDL; high density lipoprotein.
doi:10.1371/journal.pone.0160208.t001
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was less in patients with CBAV-AR. Second, fibrosis was more prominent in patients with
CBAV-AS than in those with TAV-AS and those with CBAV-AR. Third, the valvular fibrosis
was greater on the aortic side than on the ventricular side in AS patients, and it was greater in
patients with CBAV-AS than in those with CBAV-AR and TAV-AS. These findings suggest
that an inappropriate fibrotic response to chronic inflammation and neovascularization, espe-
cially on the aortic side, may contribute to the development of AS in CBAV.
Inflammation and neovascularization in CBAV-AS and TAV-AS
Previous reports suggested that CBAV-AS was associated with increased inflammation and
neovascularization compared with TAV-AS [14, 17, 18]. Increased shear stress, genetic muta-
tion, and intraleaflet hemorrhage are reported to accelerate inflammatory processes in CBA-
V-AS; however, this remains speculative. In our study, the degree of inflammation and
neovascularization were comparable between CBAV-AS and TAV-AS. Although differences in
the patients’ background, such as age, disease duration and severity of AS, might have caused
the discrepant results, the fibrotic response to inflammation rather than inflammation itself
could be related to the development of AS in CBAV. Further studies are needed to investigate
whether accelerated inflammation and neovascularization truly exist and play a role in the
rapid progression of stenosis in patients with CBAV.
Valvular fibrosis in stenotic bicuspid aortic valve
In our study, valvular fibrosis and thickness of fibrotic lesions were greater in patients with
CBAV-AS than in those with TAV-AS, despite no differences in other pathologic parameters.
Bicuspid morphology was an independent predictor of valvular fibrosis in patients with AS. In
addition, valvular fibrosis was more marked in patients with CBAV-AS than in patients with
CBAV-AR. The pathological features of CBAV-AR might reflect the initial lesions prior to the
development of CBAV-AS, since CBAV-AR usually occurs in younger patients. Our study sug-
gested that the increased fibrosis in CBAV-AS might be an acquired response.
Fig 1. Macroscopic appearances of representative excised aortic valves for aortic stenosis and regurgitation. Tricuspid aortic valve stenosis
(TAV-AS); Severe calcified sclerotic tricuspid valve with fused commissures is seen. Congenital bicuspid aortic valve stenosis (CBAV-AS); Two
calcified cusps with raphe (black arrow) and severe fibrous thickening are seen. Congenital bicuspid aortic valve regurgitation (CBAV-AR); R (right
coronary cusp) and L (left coronary cusp) are fused. Coaptation sites are rather thicker than the other portions (white arrow).
doi:10.1371/journal.pone.0160208.g001
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There are possible explanations for the association between valvular fibrosis and CBAV-AS.
First, perturbation of blood flow in CBAV causes valvular thickening and fibrosis. Although
the mechanisms by which mechanical forces invoke cellular and molecular responses within
the aortic valve are not well understood, cardiovascular tissue generally responds to increased
radial stress by increasing in thickness to buffer or neutralize mechanical stress [19]. Second,
the valvular fibrosis and progression of AS in CBAV might be related to impairment of the
nitric oxide system. A previous study using a porcine model suggested that nitric oxide inhibits
calcification processes in aortic valve cells [20]. In humans with CBAV, expression of endothe-
lial nitric oxide synthase (eNOS) in aortic endothelial cells has been reported to be significantly
reduced [21]. In fact, eNOS-deficient mice are commonly complicated with CBAV [22, 23].
Moreover, a study using eNOS knock out mice showed the development of aortic valvular
fibrosis and calcification in CBAVs, suggesting that nitric oxide deficiency might cause aortic
valve sclerosis by promoting fibrosis [24]. Therefore, it is possible that abnormality of nitric
oxide synthesis in patients with CBAV might be involved in the pathogenesis of CBAV-AS.
In terms of the thickness of fibrosis, both patients with CBAV-AS and TAV-AS had thicker
fibrosis on the aortic side than on the ventricular side. Calcification of the aortic valve usually
begins on the aortic side of valve cusps, with relative sparing of the ventricular side. The aortic
side of valve cusps is exposed to high mechanical stress of downstream flow during the diastolic
Table 2. Histopathological differences between the three groups.
TAV-AS CBAV-AS CBAV-AR p value between TAV-AS vs. CBAV-AS p value between CBAV-AS vs. CBAV-AR
Number 24 24 24
Inﬂammation
Grade 0 4 3 17 NS <0.01
Grade 1 16 18 7
Grade 2 4 3 0
Grade 3 0 0 0
Neovascularization
Grade 0 4 1 12 NS <0.01
Grade 1 13 19 11
Grade 2 7 4 1
Grade 3 0 0 0
Calcium deposit
Grade 0 0 0 15 NS <0.01
Grade 1 0 0 7
Grade 2 3 4 2
Grade 3 21 20 0
Cholesterol deposit
Grade 0 5 8 18 NS <0.01
Grade 1 12 8 4
Grade 2 6 6 2
Grade 3 1 2 0
Fibrosis
Grade 0 0 0 0 <0.01 <0.01
Grade 1 18 1 9
Grade 2 6 9 12
Grade 3 0 14 3
TAV; tricuspid aortic valve, CBAV; congenital bicuspid aortic valve, AS; aortic stenosis, AR; aortic regurgitation, NS; not signiﬁcant.
doi:10.1371/journal.pone.0160208.t002
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Fig 2. Histological and immunohistochemical findings of aortic valve in TAV-AS, CBAV-AS, and CBAV-AR. A: Inflammation; Inflammation with
CD3 is seen in each group. More inflammatory cell infiltration is noted in TAV-AS and CBAV-AS compared with CBAV-AR. Red arrows indicate T cells
infiltrations in valves. Upper photomicrographs are hematoxylin-eosin (H&E) staining, and lower photomicrographs are immunohistochemical staining for
CD3. B: Neovascularization; Neovascularizations in TAV-AS and CBAV-AS are more intensive than those in CBAV-AR. Upper photomicrographs are
H&E staining, and lower photomicrographs are immunohistochemical staining for vonWillebrand factor (vWF). Blue arrows indicate the expression of
vWF. C: Calcium deposition; The degrees of calcium deposition are higher in TAV-AS and CBAV-AS compared with CBAV-AR. Upper photomicrographs
are Masson’s trichrome (MT) staining, and lower photomicrographs are immunohistochemical staining for osteopontin (OPN). Red arrows indicate the
expression of osteopontin. D: Cholesterol deposition; The degrees of cholesterol deposition are higher in TAV-AS and CBAV-AS compared with
CBAV-AR. Photomicrographs are H&E staining. E: Fibrosis; Valvular fibrosis is more severely noted in CBAV-AS compared with TAV-AS and CBAV-AR.
Photomicrographs are MT staining. F: Immunohistochemical staining for tenascin-C. Red arrows indicate the expression of tenascin-C. Tenascin-C
deposit is more diffuse and intensive in CBAV-AS valve.
doi:10.1371/journal.pone.0160208.g002
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phase. In addition, expression of inhibitors of osteogenic signaling is significantly reduced in
endothelium from the aortic side of valve cusps [25, 26], leading to dominant calcific change
on the aortic side of valve cusps. Although it remains unknown whether mechanical stress and/
or a molecular mechanism causes fibrosis in AS patients, our study revealed that fibrosis was
also dominant on the aortic side of valve cusps.
In the present study, tenascin-C was markedly expressed in the aortic valve of patients with
CBAV-AS. Recent reports have suggested that tenascin-C is expressed in association with the
development of cardiovascular diseases, and it may accelerate or sustain fibrosis in cardiovas-
cular tissues [27–30]. The result of intense deposition of tenascin-C supports the idea that
inappropriate valvular fibrosis may be the main cause of the development of CBAV-AS. A fur-
ther study with a larger sample size is warranted.
Study Limitations
Our study had several limitations. First, the number of samples in the present study was too
small to possess sufficient statistical power. Second, the degree of the histological findings
was only classified using semi-quantitative methods. Third, in this study, we examined
specimens with advanced stage requiring aortic valve surgery for severe stenosis and/or
regurgitation. We did not investigate normal aortic valves as controls, and we did not obtain
specimens of valves with an earlier stage of stenosis and/or regurgitation. Moreover, less
valve degeneration occurs in the settings of aortic root dilatation or prolapse of the cusps,
which are the main causes of aortic regurgitation [31]. Therefore, we could not definitively
address the causes and mechanisms of stenosis and regurgitation of the aortic valve in cases
of CBAV and/or TAV. Fourth, we assessed the cholesterol deposition by H&E staining
Table 3. Multivariate linear regression analysis of aortic valvular fibrosis in patients with severe AS.
Valvular ﬁbrosis
Standardized coefﬁcient p value
Bicuspid morphology 0.84 <0.01
Age (/1 years) 0.02 0.91
Female sex -0.12 0.31
Hypertension 0.06 0.61
Diabetes mellitus 0.02 0.89
Dyslipidemia -0.07 0.52
Smoking history 0.09 0.41
AS; aortic stenosis
doi:10.1371/journal.pone.0160208.t003
Table 4. Comparison of thickness of valve and fibrotic lesions.
TAV-AS CBAV-AS CBAV-AR p value
Number 24 24 24
Thickness of valve (mm) 3.62 ± 1.31 5.39 ± 1.96 0.90 ± 0.25 <0.01
Thickness of ﬁbrotic lesions
Aortic side (mm) 0.54 ± 0.16 1.23 ± 0.65 0.34 ± 0.13 <0.01
Ventricular side (mm) 0.20 ± 0.12 0.42 ± 0.21 0.29 ± 0.15 <0.01
Continuous data are presented as mean ± standard deviation. TAV; tricuspid aortic valve, AS; aortic stenosis, CBAV; congenital bicuspid aortic valve, AR;
aortic regurgitation
doi:10.1371/journal.pone.0160208.t004
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because the snap frozen section for more specific staining such as Oil Red O was difficult to
assess due to valve calcification.
Conclusion
Inflammation, neovascularization, cholesterol deposition, and calcium deposition were more
prominent in patients with CBAV-AS than in those with CBAV-AR, but not significantly dif-
ferent between patients with CBAV-AS and those with TAV-AS. Meanwhile, fibrosis of the
aortic valve, especially on the aortic side, was significantly more severe in patients with CBA-
V-AS than in those without, suggesting a difference in the pathogenesis of AS between CBAV
and TAV.
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